PRINCETON, N.J., July 15 /PRNewswire/ -- Dr. Ian S. Cloudsdale has joined Princeton BioMolecular Research Inc. (PBMR) as Director of Business Development & Research. Dr. Cloudsdale will apply his 20 years of experience in small molecule discovery and management initialing on the new PBMR Focused Library Sets such as GPCR, Ion Channel Blocker & Kinase Inhibitors plus leading the PBMR expanding Lead Optimization services. Dr. Cloudsdale will head the development of new business opportunities with PBMR’s customers, and lead PBMR’s business expansion efforts in the custom chemistry area. He has a broad chemical background ranging from small molecule discovery to early process research. As Director of Chemistry, at Novartis Agribusiness Biotechnology Research, he led a team implementing parallel synthesis and automated purification tools for rapid lead generation of in vitro screening hits. In this capacity he was involved in the design and construction of new chemistry labs; and proposed and implemented the input strategy for in vitro high throughput screening. Dr. Cloudsdale has also held the position of Section Head, Target Identification and Assays, for Syngenta Biotechnology, Inc., where he was responsible for the development of novel High Throughput in vitro assays; determination of the essential genes in Arabidopsis, Ashbya, Drosophilla and C. Elegans; and analytical chemistry support for the whole site. The co-inventor of 24 U.S. patents covering herbicide products and manufacturing patents; Dr. Cloudsdale attended Cambridge University, Cambridge, England where he received a Bachelors degree, with 1st class honors, in Natural Sciences and a PhD in Organic Synthesis.
Dr. Kenneth C. Dallas, Chairman and CEO of PBMR commented: “I am excited that Dr. Ian Cloudsdale, a world-class research executive with a proven track record of discovery chemistry and relevant Pharmaceutical and Agro industry experience, will add significant value to PBMR’s chemistry management team. His unique knowledge, experience and strategic vision in the whole drug discovery field, combined with his business leadership abilities and outstanding personal qualities will be assets in our efforts to grow PBMR as a premier discovery research company.”
About Princeton BioMolecular Research (PBMR) Provides novel drug-type small molecules and develops advanced tools for drug discovery, enabling new generations of chemical entities and chemical technologies. PBMR is committed to providing the industry’s highest quality drug discovery services, and conducts R&D projects. It has collaborated with many leading pharmaceutical, biotechnology and genomic companies since 1997.
For more information about PBMR or specific products & custom chemistry services, please visit http://www.princetonbio.com/ or contact individual listed below.
Princeton BioMolecular Research Inc.
CONTACT: Edwin J. Holland, Vice President of Sales-Marketing, PrincetonBioMolecular Research, Inc., +1-732-355-9920
Web site: http://www.princetonbio.com/
